Alvotech
Alvotech
- Market cap
- $1.62B
Your view on ALVO
Overview
What the company does, where it operates, and who runs it.
About Alvotech
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Linda Jonsdottir
- Headquarters
- IS
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Linda Jonsdottir
- Headquarters
- IS
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product.
The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Alvotech. Starting points for Alvotech: EPS -$0.76, beta 0.18 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Alvotech. Trailing twelve-month EPS for Alvotech stands at -$0.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$8.75
average of 4 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy3
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.17 | −$0.01 | −$0.09 | $0.25 |
| Low estimate | $0.13 | −$0.01 | −$0.17 | $0.12 |
| High estimate | $0.21 | −$0.01 | −$0.03 | $0.38 |
| No. of analysts | 3 | 1 | 4 | 4 |
| Year-ago EPS | −$0.371 | −$0.091 | $0.101 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $293.10M | $171.20M | $590.82M | $737.01M |
| Low estimate | $280.25M | $167.67M | $541.05M | $690.71M |
| High estimate | $305.96M | $174.73M | $638.69M | $783.31M |
| No. of analysts | 1 | 1 | 4 | 4 |
| Year-ago revenue | $166.36M | $105.86M | $586.32M | — |
| Growth | +76.2% | +61.7% | +0.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Alvotech. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AMGNAmgen Inc. | Healthcare | Drug Manufacturers - General | $240.1B | ||
| AMPHAmphastar Pharmaceuticals, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.3B | ||
| AMRXAmneal Pharmaceuticals, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $7.6B | ||
| BIIBBiogen Inc. | Healthcare | Drug Manufacturers - General | $37.2B | ||
| COLLCollegium Pharmaceutical, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $805.8M | ||
| ETONEton Pharmaceuticals, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.8B | ||
| HROWHarrow Health, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.2B | ||
| OGNOrganon & Co. | Healthcare | Drug Manufacturers - General | $3.7B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| CRFTFBC Craft Supply Co. Ltd. | Healthcare | OTC | $23 | ||
| CRLBFCresco Labs Inc. | Healthcare | OTC | $350.4M | ||
| CRONCronos Group Inc. | Healthcare | NASDAQ | $1.2B | ||
| CRON.TOCronos Group Inc. | Healthcare | TSX | $1.7B | ||
| CRYMCryomass Technologies Inc. | Healthcare | OTC | $47,432 | ||
| CSTFCuraScientific Corp | Healthcare | OTC | $377,345 | ||
| CSWYFChina Shineway Pharmaceutical Group Limited | Healthcare | OTC | $758.4M | ||
| CSWYYChina Shineway Pharmaceutical Group Limited | Healthcare | OTC | $36.4M | ||
| CURA.TOCuraleaf Holdings, Inc. | Healthcare | TSX | $2.7B | ||
| CURLFCuraleaf Holdings, Inc. | Healthcare | OTC | $1.9B | ||
| CVGR.CNCity View Green Holdings Inc. | Healthcare | CNQ | $3.7M | ||
| CVGRFCity View Green Holdings Inc. | Healthcare | OTC | $1.2M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VWOVanguard FTSE Emerging Markets ETF | $125.4B in assets | 0.01% | |
| IBBiShares Biotechnology ETF | $11.1B in assets | 0.05% | |
| VEUVanguard FTSE All-World ex-US ETF | $68.1B in assets | 0.00% | |
| IBBQInvesco Nasdaq Biotechnology ETF | $130M in assets | 0.10% | |
| PRFZInvesco RAFI US 1500 Small-Mid ETF | $2.6B in assets | 0.01% | |
| VEE.TOVanguard FTSE Emerging Markets All Cap Index ETF | $4.4B in assets | 0.01% | |
| VSGXVanguard ESG International Stock ETF | $6.7B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in ALVO.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Alvotech, and how their positions are changing. At a $1.62B market value, institutional positions materially move Alvotech's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Alvotech. Coverage tracks Alvotech within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Alvotech.